- Home
- RNA vs PCVX Comparison
RNA vs PCVX Comparison
Compare RNA & PCVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RNA | PCVX |
|---|---|---|
| Founded | 2012 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.0B | 6.0B |
| IPO Year | 2020 | 2020 |
Fundamental Metrics
Financial Performance| Metric | RNA | PCVX |
|---|---|---|
| Price | $71.63 | $46.57 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 20 | 7 |
| Target Price | $69.26 | ★ $101.67 |
| AVG Volume (30 Days) | ★ 2.9M | 1.5M |
| Earning Date | 11-10-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $20,868,000.00 | N/A |
| Revenue This Year | $64.11 | N/A |
| Revenue Next Year | $37.25 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 106.27 | N/A |
| 52 Week Low | $21.51 | $27.66 |
| 52 Week High | $71.79 | $94.60 |
Technical Indicators
Market Signals| Indicator | RNA | PCVX |
|---|---|---|
| Relative Strength Index (RSI) | 77.56 | 51.97 |
| Support Level | $71.42 | $43.78 |
| Resistance Level | $71.76 | $48.11 |
| Average True Range (ATR) | 0.41 | 1.99 |
| MACD | -0.73 | -0.49 |
| Stochastic Oscillator | 88.32 | 42.99 |
Price Performance
Historical ComparisonAbout RNA Avidity Biosciences Inc.
Avidity Biosciences Inc is a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates, or AOCs. Company's pipeline currently has three programs in potentially registrational clinical trials: DM1, FSHD, and DMD. The segments includes following: Del-zota for DMD44, Del-desiran for DM1, Del-brax for FSHD.
About PCVX Vaxcyte Inc.
Vaxcyte Inc is a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its product comprises of Pneumococcal conjugate vaccine. The firm's product candidate consists of VAX-31, VAX-24, VAX-A1, VAX-PG, VAX-GI, and Others.